Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global colorectal cancer therapeutics market was valued at US$ 10.6 billion in 2021 and is expected to register a revenue CAGR of 9.80% to reach US$ 24.58 billion by 2030.

Colorectal Cancer Therapeutics Market Fundamentals

The latest colorectal cancer therapeutics market trends include growing awareness about cancer treatment solutions among the general population. Furthermore, a strong product pipeline, particularly for metastatic colorectal cancer, is expected to determine the future of the colorectal cancer therapeutics market. Advancements in diagnosis techniques and their improving accuracy have also led to early diagnosis and treatment of colorectal cancer. This factor is creating profitable opportunities in the global colorectal cancer therapeutics market. The prominent colorectal cancer therapeutics include Keytruda, Stivarga, Jemperli, Braftovi, Cyramza, Lonsurf, Opdivo, and Vectibix. Considering the future landscape, the major pipeline candidates in the colorectal cancer therapeutics market include Adagrasib, Lynparza, Elunate, MK-4280A, Corsela, and Lenvima. 

Colorectal cancer or colon cancer develops in the tissues of the colon, which is the longest part of the large intestine. Most colon cancers are adenocarcinomas that begin with abnormal proliferation of cells and make them release mucus and other fluids. As age progresses, the possibility of colorectal cancer increases. Although young adults and teenagers can develop colorectal cancer, individuals with 50+ age are at higher risk of developing the disease. For men with colon cancer, the average age of diagnosis is 68 years. On the other hand, this age is 72 years for women. Risk factors for developing colorectal cancer include an unhealthy diet, tobacco smoking, and heavy alcohol usage. Additionally, those who have a family history of colorectal cancer or certain hereditary cancer conditions are at increased risk of acquiring the disease.

[897546]

Colorectal Cancer Therapeutics Market Dynamics

The colorectal cancer therapeutics market is expected to gain significant revenue growth during the forecast period owing to increasing prevalence of colorectal cancer, rising aging population, and growing number of clinical trials to develop novel treatments for this disease.

However, high expenditures on therapeutics are likely to restrain the revenue growth of the global colorectal cancer therapeutics market during the forecast period. 

Colorectal Cancer Therapeutics Market Ecosystem

The global colorectal cancer therapeutics market is analyzed based on four parameters: therapy, cancer type, end user, and region. 

Global Colorectal Cancer Therapeutics Market by Therapy

[617835]

Based on the therapy, the global market for colorectal cancer therapeutics is segmented into chemotherapy, immunotherapy, and targeted therapy. 

The targeted therapy segment dominates the therapy segment. The targeted therapy can help the immune system of an individual to locate and eliminate cancer cells in the body more effortlessly. This aside, the therapy also improves the ability of an immune system to fight cancer. 

Chemotherapy inhibits the growth of tumors and helps in reducing symptoms. It can reduce the number of cancer patients susceptible to surgical resection. Additionally, chemotherapy spreads throughout the body, aiding in the elimination of cancer cells that may proliferate in various body parts. 

Immunotherapy selectively targets cancer antigens on tumor cells. It alerts the immune system about the presence of foreign agents and uses a coordinated immune response to destroy cancer.

Global Colorectal Cancer Therapeutics Market by Cancer Type

Based on the cancer type, the global colorectal cancer therapeutics market is segmented into adenocarcinoma, gastrointestinal carcinoid tumors, and others (gastrointestinal stromal tumors and familial colorectal cancer). 

The colorectal adenocarcinoma segment dominates the market in terms of revenue share. This can be attributed to increasing prevalence of adenocarcinoma. Moreover, availability of novel drugs with a larger market share is supporting the revenue growth of the colorectal adenocarcinoma segment. 

Slow-growing cancers called carcinoid tumors can develop in many locations throughout the body. Neuroendocrine tumors, which include carcinoid tumors, typically start in the digestive system (stomach, appendix, small intestine, colon, or rectum) or the lungs.

Various new approaches came into action to offer better therapeutics. For instance, Octreotide or Lanreotide, which are administered subcutaneously or intramuscularly, are used as hormone therapy for gastrointestinal carcinoid tumors. Octreotide and lanreotide restrict the proliferation rate of tumors.

Global Colorectal Cancer Therapeutics Market by Region 

Based on the region, the colorectal cancer therapeutics market is segmented into North America, Europe, Asia Pacific, and the Rest of the world (RoW). 

In terms of revenue share, North America dominates the global market for colorectal cancer therapeutics. The primary factor supporting the revenue growth is high prevalence of colon cancer, greater adoption of novel therapeutics, and increased health awareness among the regional population. 

The Europe market is expected to register significant revenue growth during the forecast period, due to presence of a large geriatric population prone to colorectal cancer, improved diagnostics practices, and increased initiatives taken by the regional government for effectual treatment of colorectal cancer. 

The market in Asia Pacific is expected to register high revenue growth during the forecast period due to evolving healthcare systems, rising prevalence of colon cancer, and improving reimbursement policies in the region. 

Colorectal Cancer Therapeutics Market Competitive Landscape

The prominent players operating in the global colorectal cancer therapeutics market are: 

• Merck Sharp & Dohme Corp.
• Bayer AG 
• Bristol Myers Squibb Holdings
• Elli Lilly and Company
• Johnson & Johnson Services, Inc. 
• Amgen Inc. 
• Celleron Therapeutics Limited
• Sumitomo Pharma Co., Ltd
• Teva Pharmaceutical Industries, Ltd. 
• AbbVie Inc. 
• Novartis AG
• Sanofi AG

Strategic Development/s

• In May 2020, the U.S. FDA (Food and Drug Administration) approved encorafenib in combination with cetuximab to treat metastatic colorectal cancer, whose tumors have a specific mutation in the BRAF gene, called V600E

Frequently Asked Questions About This Report